Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Maria Gonzalez-Angulo

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Cancer Cell|October 16, 2007
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancerKatrien Berns, Hugo M Horlings, Bryan T Hennessy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2014
Influence of biospecimen variables on proteomic biomarkers in breast cancerFunda Meric-Bernstam, Argun Akcakanat, Huiqin Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2009
Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancerRoshan Agarwal, Ana-Maria Gonzalez-Angulo, Simen Myhre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancerBryan T J Hennessy, Kirsten M Timms, Mark S Carey, et al.
Clinical Proteomics|June 22, 2011
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast CancersBryan T Hennessy, Yiling Lu, Ana Maria Gonzalez-Angulo, et al.
Breast Cancer Research : BCR|July 12, 2014
Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancerPatrick C O'Leary, Marta Terrile, Malgorzata Bajor, et al.
Cancer Research|August 5, 2008
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancerKatherine Stemke-Hale, Ana Maria Gonzalez-Angulo, Ana Lluch, et al.
Plos One|March 9, 2016
Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient OutcomesPriscilla F McAuliffe, Kurt W Evans, Argun Akcakanat, et al.
Plos One|September 2, 2015
Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient OutcomesPriscilla F McAuliffe, Kurt W Evans, Argun Akcakanat, et al.
Cancer Research|May 14, 2009
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristicsBryan T Hennessy, Ana-Maria Gonzalez-Angulo, Katherine Stemke-Hale, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Cancer Cell|October 16, 2007
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancerKatrien Berns, Hugo M Horlings, Bryan T Hennessy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2014
Influence of biospecimen variables on proteomic biomarkers in breast cancerFunda Meric-Bernstam, Argun Akcakanat, Huiqin Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2009
Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancerRoshan Agarwal, Ana-Maria Gonzalez-Angulo, Simen Myhre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancerBryan T J Hennessy, Kirsten M Timms, Mark S Carey, et al.
Clinical Proteomics|June 22, 2011
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast CancersBryan T Hennessy, Yiling Lu, Ana Maria Gonzalez-Angulo, et al.
Breast Cancer Research : BCR|July 12, 2014
Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancerPatrick C O'Leary, Marta Terrile, Malgorzata Bajor, et al.
Cancer Research|August 5, 2008
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancerKatherine Stemke-Hale, Ana Maria Gonzalez-Angulo, Ana Lluch, et al.
Plos One|March 9, 2016
Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient OutcomesPriscilla F McAuliffe, Kurt W Evans, Argun Akcakanat, et al.
Plos One|September 2, 2015
Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient OutcomesPriscilla F McAuliffe, Kurt W Evans, Argun Akcakanat, et al.
Cancer Research|May 14, 2009
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristicsBryan T Hennessy, Ana-Maria Gonzalez-Angulo, Katherine Stemke-Hale, et al.
Pageof 8